By targeting IL-33, the therapeutic effect of BRCA can be enhanced by regulating excessive immune responses, reducing inflammatory damage, or fighting tumor cells by enhancing immune responses (Donahue et al., 2024). The gene discussed is IL33; the disease is neoplasm.